Novel filagrinol-containing emollient

Background. In the last decade, there has been a significant increase in interest study of role epidermal barrier structural integrity order to determine prospects for its pathogenetic correction. It is now known that patients with filaggrin gene mutations have increased risk developing atopic dermatitis, xerosis, ichthyosis, eczema. Filaggrin participates formation full-fledged stratum corneum, provides natural moisturizing factor, stabilizing water balance corneum. Russia, innovative filaggrin-containing Admera registered, which opens up management impaired skin function diseases.
 Aims. Efficacy and safety "Admera" emollient primary secondary xerosis.
 Materials methods. A single-center prospective interventional December 2021 March 2022 at Department Skin Venereal Diseases Sechenov University. The included 32 (22 main group, 10 control group) aged 18 60 years (29 9.78), 14 men women diagnosed xerosis. Patients applied moisturizers 3 times day 21 days. Performance was evaluated using vIGA-AD, POEM, EASI, 5D Elman scale, SKINDEX-29, HADS, on Capricorn AI, ANTERA 3D machines.
 Results. steady regression clinical symptoms xerosis noted during by dynamics scales. mean EASI score decreased 67% from 25.25 18.78 screening 7.8 4.41 visit (p 0.001). Assessment POEM index showed decrease total 18.65 6.6 There good tolerability product absence adverse events.
 Conclusions. filagrinol-containing (Dr. Reddy's Laboratories Ltd., India) demonstrated high efficacy all patients. This can be recommended as basic care treatment schemes prevention primary, relapses dermatitis.